



## Key facts about uveitis

- Uveitis is one of the leading causes of blindness in developing countries causing about 15% of total blindness cases.\*
- It is a group of approximately 30 diseases characterized by intraocular inflammation.\*
- Non-infectious causes include many autoimmune diseases such as ankylosing spondylitis and multiple sclerosis.
- Infectious causes include diseases such as syphilis or herpes simplex virus.

## What is Uveitis?

- Uveitis is an inflammatory condition of the eye affecting mainly the uvea, or middle layer of the eye.
- Symptoms of the different types of uveitis include ocular pain, light sensitivity, redness of the eye, decreased vision, dark spots or blurred vision, and eventual loss of vision.
- Anatomically, uveitis is classified by the main site of inflammation as anterior, intermediate, posterior, and panuveitis.
- Uveitis can be caused by systemic autoimmune disorders, such as Behçet's disease and Vogt-Koyanagi-Harada (VKH) disease; infections, including toxoplasmosis and syphilis; or trauma and surgery. However, the majority of uveitis cases are idiopathic, meaning that the cause is unknown.

## Patient Impact

- Uveitis patients suffer with a reduced quality of life due to the vision loss impacting their daily lives.
- One study has shown that along with the lower quality of life, their mental health can be negatively impacted and potentially lead to depression.\*
- Patients have also reported reduced overall ability to read, drive, and work.

## Treatment options


- The first-line treatment for uveitis consists of various forms of corticosteroids, which are often used in conjunction with antimetabolites and alkylating agents. All of these treatments rely on non-specific immunosuppression for their efficacy.
- These steroids range in formulation from eye drops to ocular injections to slow-release implants.
- TNF-alpha-inhibiting antibodies and have been used to treat uveitis patients with ranging success rates along with having immunosuppressive effects.
- Besides corticosteroids and biologic immune-suppressing drugs, there are not many other options for a patient to use.

\* GlobalData Uveitis – Opportunity Analysis and Forecasts to 2017  
Image: <http://images.wisegeek.com/girl-using-eye-drops.jpg>

# Uveitis

## Epidemiology

- In 2014 there were 680,000 prevalent cases of uveitis in the US and EU growing to 731,000 in 2022 with an average annual growth rate of 0.98%.\*
- Groups with higher rates of uveitis include smokers, HLA gene positive individuals, and people with other autoimmune diseases.\*
- Uveitis is rare in children (only about 10% of cases) and slightly more common in women than in men.\*
- US prevalence in 2014 was about 366,000 with about 37% of patients having severe uveitis.\*



Source: GlobalData EpiCast: Uveitis - Epidemiology Forecasts to 2022

Treatment options for uveitis are severely limited. Both patients and physicians need a larger variety of therapies that are safer to address the growing global prevalence of the disease.

## Unmet Needs of Uveitis

- Therapies to prevent loss of eyesight and control inflammation
- Safer products with fewer side effects
- Simplified and less frequent dosing of therapies
- More novel mechanisms of action to treat the disease onset and progression rather than only the symptoms
- Raise disease awareness among physicians and patients\*

## About KPI Therapeutics<sup>TM</sup>:

KPI Therapeutics is a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity using its novel Kv1.3 channel blocker based platform. Its lead drug, dalazatide is being clinically advanced for Inclusion Body Myositis, (IBM) an orphan disease, and for lupus. Our autoimmune platform molecules are also being developed for new therapies to address atopic dermatitis and uveitis.

Our KPI-190 program is developing a topical biologic Kv1.3 inhibitor targeting the immune cells that cause uveitis.

[www.kpitherapeutics.com](http://www.kpitherapeutics.com) | 206-788-4600

\* GlobalData Uveitis – Opportunity Analysis and Forecasts to 2017  
Image: <http://images.wisegeek.com/girl-using-eye-drops.jpg>